Carvykti
Carvykti is a medicine authorised by Swissmedic under authorisation number 67956. The authorisation holder is Janssen-Cilag AG. The medicinal product code is Transplant: gene therapy product and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 08 August 2022 and the authorisation is limited until 07 August 2027. ATC code L01XL05 places the medicine in the group Antineoplastic agents.
| Authorisation number | 67956 |
|---|---|
| Name | Carvykti |
| Full name | Carvykti |
| Authorisation holder | Janssen-Cilag AG |
| Medicinal product code | Transplant: gene therapy product |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | L01XL05 |
| First authorisation | 08 August 2022 |
| Authorisation validity | 07 August 2027 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Carvykti | A | 08 August 2022 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 1x30 oder 70ml | Beutel | L01XL05 | 07.16.4. | A |
Scroll the table sideways
Other medicines from this authorisation holder
Frequently asked questions
Is Carvykti authorised in Switzerland?
Yes. Carvykti is authorised by Swissmedic under authorisation number 67956, data as of 01 September 2026. The authorisation is limited until 07 August 2027.
Which dispensing category does Carvykti have?
Carvykti is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of Carvykti?
The authorisation holder is Janssen-Cilag AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.